JBIO

$0.00

(

+0.00%

)
Quote details

stock

Jade Biosciences, Inc.

NASDAQ | JBIO

9.09

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 13, 2025)

$280.13M

Market Cap

-

P/E Ratio

-

EPS

$102.31

52 Week High

$6.57

52 Week Low

HEALTHCARE

Sector

JBIO Chart

Recent Chart
Price Action

JBIO Technicals

Tags:

JBIO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (None)
Gross Profit -$282K
Total Revenue -
Cost Of Revenue $282K
Costof Goods And Services Sold $282K
Operating Income -$71K
Selling General And Administrative $8.6K
Research And Development $62K
Operating Expenses $71K
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $64K
Income Before Tax -$94K
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -
Comprehensive Income Net Of Tax -
Ebit -
Ebitda -
Net Income -$94K

Revenue & Profitability

Earnings Performance

JBIO Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (None)
Total Assets $73K
Total Current Assets $70K
Cash And Cash Equivalents At Carrying Value $34M
Cash And Short Term Investments $34M
Inventory -
Current Net Receivables -
Total Non Current Assets $3.1K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $45M
Other Current Assets -$79M
Other Non Current Assets -
Total Liabilities $120K
Total Current Liabilities $12K
Current Accounts Payable $1.3K
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $108K
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $108K
Other Current Liabilities $11K
Other Non Current Liabilities -
Total Shareholder Equity -$47K
Treasury Stock -
Retained Earnings -$47K
Common Stock $1
Common Stock Shares Outstanding $5K

yearly Cash Flow (As of Dec 31, 2024)

Field Value (None)
Operating Cashflow -$71M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $56M
Cashflow From Financing $25M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$94K

yearly Income Statement (As of Dec 31, 2024)

Field Value (None)
Gross Profit -$282K
Total Revenue -
Cost Of Revenue $282K
Costof Goods And Services Sold $282K
Operating Income -$71K
Selling General And Administrative $8.6K
Research And Development $62K
Operating Expenses $71K
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $64K
Income Before Tax -$94K
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -
Comprehensive Income Net Of Tax -
Ebit -
Ebitda -
Net Income -$94K

Dividends

Field Value
Ex Dividend Date 2025-04-25
Declaration Date 2025-04-09
Record Date 2025-04-25
Payment Date 2025-04-29
Amount 2.4

JBIO News

JBIO Profile

Jade Biosciences, Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Jade Biosciences, Inc. is a biotechnology firm based in Waltham, Massachusetts, focused on advancing innovative therapies for inflammation and immunology disorders, particularly targeting autoimmune diseases. The company is dedicated to addressing unmet medical needs through its proprietary drug development pipeline, leveraging cutting-edge research to improve patient outcomes. With a commitment to scientific excellence and a growing portfolio, Jade Biosciences is positioned to make significant contributions to the field of immunotherapy.

VHAI
-25.00%
$0.00
YYAI
-10.47%
$0.17
BURU
+7.74%
$0.51
CGBS
-39.47%
$0.03
ELBM
+325.45%
$7.02
PLUG
+14.03%
$3.90
RGTI
+25.02%
$54.91
GWH
+117.54%
$9.05
BITF
+28.33%
$5.39
NVDA
+2.81%
$188.32
ASST
-30.54%
$1.08
IONZ
-32.55%
$2.29
BYND
-48.50%
$1.03
NVTS
+21.14%
$9.97
INTC
+2.33%
$37.22
JOBY
+3.00%
$16.77
DNN
+6.94%
$3.08
GPUS
-10.39%
$0.43
CAN
+39.44%
$1.52
QBTS
+23.01%
$40.61
TSLA
+5.41%
$435.90
BBD
+0.98%
$3.09
F
+1.13%
$11.54
CLF
+4.93%
$13.83
AXDX
-61.36%
$0.03
NIO
+7.00%
$7.18
QS
+15.57%
$16.98
SOFI
+3.62%
$27.14
CRML
+55.40%
$23.28
ETHD
-12.82%
$3.33
CIFR
+19.85%
$20.34
ACHR
+6.68%
$12.77
RXRX
+3.94%
$5.53
SOUN
+10.25%
$19.14
DFLI
+44.03%
$1.57
APLD
+0.73%
$34.24
TLRY
-1.74%
$1.69
BTBT
+6.38%
$4.00
NAK
+31.03%
$2.66
AMD
+0.40%
$215.76
LAES
+13.30%
$6.13
ONDS
+17.24%
$10.81
DVLT
-10.52%
$1.70
MP
+21.34%
$95.06
USAR
+18.61%
$38.68
RR
+8.95%
$6.45
IREN
+7.31%
$64.14
AVGO
+9.87%
$356.70
UAMY
+36.85%
$16.71
ABAT
+36.59%
$9.22
PFE
-0.20%
$24.73
SNAP
+3.47%
$8.05
NAKA
-1.56%
$0.85
RIG
+3.89%
$3.20
IONQ
+16.19%
$82.09
AAL
+1.90%
$11.74
QUBT
+12.85%
$21.46
UUUU
+16.86%
$23.77
MARA
+8.52%
$20.23
NOK
-1.31%
$5.25
EOSE
+23.37%
$17.05
BMNR
+8.34%
$56.85
PLTR
+1.00%
$177.21
RMBL
+60.50%
$3.21
ADAP
-2.59%
$0.18
EPWK
-8.00%
$0.08
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AAPL
+0.97%
$247.66
AMZN
+1.71%
$220.07
WULF
+3.62%
$14.00
XCH
+103.41%
$1.68
T
-1.08%
$25.59
HPE
+1.63%
$24.80
RF
+1.65%
$24.56
NB
+8.95%
$11.32
SRM
+53.27%
$10.30
BTG
+4.52%
$5.31
CLSK
+3.94%
$20.04
GDXD
-13.62%
$0.73
BAC
+0.43%
$48.86
QSI
+24.55%
$2.08
KDP
+2.32%
$26.42
RGTZ
-50.00%
$9.30
VALE
+2.41%
$11.01
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
SLB
+1.73%
$32.27
ORCL
-1.34%
$292.95
ABEV
+1.42%
$2.14
BE
+26.52%
$109.91
WLGS
-5.57%
$0.04
TMC
+20.31%
$10.69
HOOD
+1.23%
$140.68
TMQ
+10.62%
$6.56
GRAB
+1.19%
$5.93
KDLY
-7.21%
$0.87
GGB
+2.85%
$3.24
ETWO
0.00%
$3.30
VHAI
-25.00%
$0.00
YYAI
-10.47%
$0.17
BURU
+7.74%
$0.51
CGBS
-39.47%
$0.03
ELBM
+325.45%
$7.02
PLUG
+14.03%
$3.90
RGTI
+25.02%
$54.91
GWH
+117.54%
$9.05
BITF
+28.33%
$5.39
NVDA
+2.81%
$188.32
ASST
-30.54%
$1.08
IONZ
-32.55%
$2.29
BYND
-48.50%
$1.03
NVTS
+21.14%
$9.97
INTC
+2.33%
$37.22
JOBY
+3.00%
$16.77
DNN
+6.94%
$3.08
GPUS
-10.39%
$0.43
CAN
+39.44%
$1.52
QBTS
+23.01%
$40.61
TSLA
+5.41%
$435.90
BBD
+0.98%
$3.09
F
+1.13%
$11.54
CLF
+4.93%
$13.83
AXDX
-61.36%
$0.03
NIO
+7.00%
$7.18
QS
+15.57%
$16.98
SOFI
+3.62%
$27.14
CRML
+55.40%
$23.28
ETHD
-12.82%
$3.33
CIFR
+19.85%
$20.34
ACHR
+6.68%
$12.77
RXRX
+3.94%
$5.53
SOUN
+10.25%
$19.14
DFLI
+44.03%
$1.57
APLD
+0.73%
$34.24
TLRY
-1.74%
$1.69
BTBT
+6.38%
$4.00
NAK
+31.03%
$2.66
AMD
+0.40%
$215.76
LAES
+13.30%
$6.13
ONDS
+17.24%
$10.81
DVLT
-10.52%
$1.70
MP
+21.34%
$95.06
USAR
+18.61%
$38.68
RR
+8.95%
$6.45
IREN
+7.31%
$64.14
AVGO
+9.87%
$356.70
UAMY
+36.85%
$16.71
ABAT
+36.59%
$9.22
PFE
-0.20%
$24.73
SNAP
+3.47%
$8.05
NAKA
-1.56%
$0.85
RIG
+3.89%
$3.20
IONQ
+16.19%
$82.09
AAL
+1.90%
$11.74
QUBT
+12.85%
$21.46
UUUU
+16.86%
$23.77
MARA
+8.52%
$20.23
NOK
-1.31%
$5.25
EOSE
+23.37%
$17.05
BMNR
+8.34%
$56.85
PLTR
+1.00%
$177.21
RMBL
+60.50%
$3.21
ADAP
-2.59%
$0.18
EPWK
-8.00%
$0.08
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AAPL
+0.97%
$247.66
AMZN
+1.71%
$220.07
WULF
+3.62%
$14.00
XCH
+103.41%
$1.68
T
-1.08%
$25.59
HPE
+1.63%
$24.80
RF
+1.65%
$24.56
NB
+8.95%
$11.32
SRM
+53.27%
$10.30
BTG
+4.52%
$5.31
CLSK
+3.94%
$20.04
GDXD
-13.62%
$0.73
BAC
+0.43%
$48.86
QSI
+24.55%
$2.08
KDP
+2.32%
$26.42
RGTZ
-50.00%
$9.30
VALE
+2.41%
$11.01
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
SLB
+1.73%
$32.27
ORCL
-1.34%
$292.95
ABEV
+1.42%
$2.14
BE
+26.52%
$109.91
WLGS
-5.57%
$0.04
TMC
+20.31%
$10.69
HOOD
+1.23%
$140.68
TMQ
+10.62%
$6.56
GRAB
+1.19%
$5.93
KDLY
-7.21%
$0.87
GGB
+2.85%
$3.24
ETWO
0.00%
$3.30

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.